Suppr超能文献

患有炎症性肠病的小鼠易感染艰难梭菌,且病情严重。

Mice with Inflammatory Bowel Disease are Susceptible to Clostridium difficile Infection With Severe Disease Outcomes.

机构信息

Institute of Antibiotics, Huashan Hospital, Fudan University, Shanghai, China.

Department of Microbial Pathogenesis, University of Maryland School of Dentistry, Baltimore, Maryland, USA.

出版信息

Inflamm Bowel Dis. 2018 Feb 15;24(3):573-582. doi: 10.1093/ibd/izx059.

Abstract

BACKGROUND

Over the past several decades, there has been a significant increase in the incidence of Clostridium difficile infection (CDI) in patients suffering from inflammatory bowel disease (IBD). However, a wild-type animal model is not available to study these comorbid diseases.

METHODS

We evaluated the susceptibility to CDI of mice with dextran sulfate sodium salt (DSS)-induced colitis (IBD mice) with or without antibiotic exposure; we examined the histopathology and cytokine response in the concomitant diseases after the model was created.

RESULTS

No CDI occurs in healthy control mice, wherease the incidence of CDI in IBD mice is 40%; however, in IBD mice that received antibiotics, the incidence of CDI is 100% and the disease is accompanied by high levels of toxins in the mouse feces and sera. Compared to IBD and CDI alone, those IBD mice infected with C. difficile have more severe symptoms, toxemia, histopathological damage, and higher mortality. Moreover, several proinflammatory cytokines and chemokines are significantly elevated in the colon tissues from IBD mice infected with C. difficile.

CONCLUSIONS

We, for the first time, demonstrate in an animal model that mice with dextran sulfate sodium induced-inflammatory bowel disease are significantly more susceptible to C. difficile infection, and that the bacterial infection led to more severe disease and death. These findings are consistent with clinical observations, thus, the animal model will permit us to study the pathogenesis of these concurrent diseases and to develop therapeutic strategies against the comorbidity of IBD and CDI.

摘要

背景

在过去几十年中,患有炎症性肠病(IBD)的患者中艰难梭菌感染(CDI)的发病率显着增加。然而,目前尚无野生型动物模型可用于研究这些合并疾病。

方法

我们评估了经葡聚糖硫酸钠盐(DSS)诱导结肠炎(IBD 小鼠)的小鼠对 CDI 的易感性,以及有无抗生素暴露;我们在建立模型后检查了合并疾病的组织病理学和细胞因子反应。

结果

健康对照小鼠中未发生 CDI,而 IBD 小鼠中 CDI 的发生率为 40%;然而,在接受抗生素的 IBD 小鼠中,CDI 的发生率为 100%,并且疾病伴随着粪便和血清中高水平的毒素。与 IBD 和 CDI 单独相比,感染艰难梭菌的 IBD 小鼠具有更严重的症状,中毒,组织病理学损伤和更高的死亡率。此外,在感染艰难梭菌的 IBD 小鼠的结肠组织中,几种促炎细胞因子和趋化因子显着升高。

结论

我们首次在动物模型中证明,用葡聚糖硫酸钠诱导的炎症性肠病的小鼠对艰难梭菌感染的敏感性显着增加,并且细菌感染导致更严重的疾病和死亡。这些发现与临床观察一致,因此,该动物模型将使我们能够研究这些合并疾病的发病机制,并制定针对 IBD 和 CDI 合并症的治疗策略。

相似文献

5
Clostridium difficile and inflammatory bowel disease: role in pathogenesis and implications in treatment.
World J Gastroenterol. 2013 Nov 21;19(43):7577-85. doi: 10.3748/wjg.v19.i43.7577.
6
Clostridium difficile infection in patients with inflammatory bowel disease: a case control study.
Scand J Gastroenterol. 2018 Aug;53(8):947-951. doi: 10.1080/00365521.2018.1492012. Epub 2018 Jul 25.
7
Clostridium difficile infection in Polish pediatric outpatients with inflammatory bowel disease.
Eur J Clin Microbiol Infect Dis. 2010 Oct;29(10):1265-70. doi: 10.1007/s10096-010-0997-9. Epub 2010 Jun 26.
9
Host Immune Response to Clostridium difficile Infection in Inflammatory Bowel Disease Patients.
Inflamm Bowel Dis. 2016 Apr;22(4):853-61. doi: 10.1097/MIB.0000000000000696.

引用本文的文献

1
in Animal Inflammatory Bowel Disease: A One Health Perspective on Emerging Zoonotic Threats.
Microorganisms. 2025 May 28;13(6):1233. doi: 10.3390/microorganisms13061233.
3
The role of the enteric nervous system in the pathogenesis of Clostridioides difficile infection.
Nat Rev Gastroenterol Hepatol. 2025 May 22. doi: 10.1038/s41575-025-01071-x.
6
RNA-Based Anti-Inflammatory Effects of Membrane Vesicles Derived from .
Foods. 2024 Mar 21;13(6):967. doi: 10.3390/foods13060967.
7
Transplant of microbiota from Crohn's disease patients to germ-free mice results in colitis.
Gut Microbes. 2024 Jan-Dec;16(1):2333483. doi: 10.1080/19490976.2024.2333483. Epub 2024 Mar 27.
8
Clostridioides difficile infection promotes gastrointestinal dysfunction in human and mice post-acute phase of the disease.
Anaerobe. 2024 Jun;87:102837. doi: 10.1016/j.anaerobe.2024.102837. Epub 2024 Mar 26.
9
evaluation of enoyl-ACP reductase II (FabK) inhibition by phenylimidazole unveils a promising narrow-spectrum antimicrobial strategy.
Antimicrob Agents Chemother. 2024 Mar 6;68(3):e0122223. doi: 10.1128/aac.01222-23. Epub 2024 Jan 24.

本文引用的文献

1
Management Strategies to Improve Outcomes of Patients With Inflammatory Bowel Diseases.
Gastroenterology. 2017 Feb;152(2):351-361.e5. doi: 10.1053/j.gastro.2016.09.046. Epub 2016 Oct 5.
3
5
Methods of Inducing Inflammatory Bowel Disease in Mice.
Curr Protoc Pharmacol. 2016 Mar 18;72:5.58.1-5.58.42. doi: 10.1002/0471141755.ph0558s72.
7
Association Between Circulating Levels of C-Reactive Protein and Interleukin-6 and Risk of Inflammatory Bowel Disease.
Clin Gastroenterol Hepatol. 2016 Jun;14(6):818-824.e6. doi: 10.1016/j.cgh.2016.01.016. Epub 2016 Feb 1.
10
Clostridium difficile infection aggravates colitis in interleukin 10-deficient mice.
World J Gastroenterol. 2014 Dec 7;20(45):17084-91. doi: 10.3748/wjg.v20.i45.17084.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验